Précis: The Hydrus Microstent combined cataract surgery reduces IOP and medication use in mild-to-moderate glaucoma. For severe open angle glaucoma, it reduces medication use while maintaining a favorable safety profile. Purpose: This study evaluates the 12-month clinical outcomes of Hydrus Microstent combined with cataract surgery in eyes with open angle glaucoma stratified by disease severity. Materials and Methods: Retrospective, single-surgeon cohort study. Eyes with mild-to-moderate and severe glaucoma undergoing Hydrus implantation combined with cataract surgery were included. Primary outcomes were complete (no medication) and qualified (with medication) success (6–21 mm Hg) at 1 year. Secondary outcomes included IOP, number of glaucoma medications, complications, failure, and success rates for 6–18 and 6–15 mm Hg IOP thresholds. Results: A total of 147 eyes from 100 patients with a median baseline IOP of 16.0 [IQR: 14.0–20.0] on 2.0 [1.0–3.0] medications were included. Complete success was achieved in 78% and qualified success in 93% of eyes, with mild-to-moderate glaucoma achieving 77% and 92%, and severe glaucoma achieving 84% and 96%, respectively. In the mild-to-moderate group, mean IOP decreased from 17.1±3.8 mm Hg (SD) to 15.5±2.7 mm Hg ( P <0.0003), and medications were reduced from 2.2±1.1 to 0.6±1.1 ( P <0.0001). In the severe group, mean IOP was not significantly changed, and medications were reduced from 2.6±1.3 to 1.2±1.3 ( P =0.0008). At 12 months, 64% of eyes were medication-free, and 67% of severe cases required one or fewer medications. Focal peripheral anterior synechiae (35%) was the most common complication. Conclusion: The Hydrus Microstent lowered medication use across all glaucoma severities. Further studies with larger sample sizes are warranted to support these findings.
To evaluate the incidence, risk factors, management strategies, and visual outcomes of retinal detachment (RD) following Boston Keratoprosthesis Type 1 (KPro) implantation. Single-center, retrospective observational case series. Medical records of 157 eyes from 122 adult patients who underwent Boston Type 1 KPro implantation at a tertiary care center between 2008 and 2022 were reviewed. Inclusion criteria included age ≥18 years and postoperative follow-up of at least 1 year. Demographic data, preoperative characteristics, postoperative complications, and visual outcomes were collected. Univariate and multivariate statistical analyses were conducted to identify significant risk factors for RD. Cox regression and Kaplan-Meier survival analysis were used to evaluate time-to-event data. Of the 157 eyes that underwent Boston Type 1 KPro implantation, 27 eyes (17.2%) developed retinal detachment (RD), all within 8 years postoperatively (2 RD per 100 eye years). Aniridia was significantly associated with increased RD risk (OR: 2.79; 95% CI: 1.23-6.70), while other preoperative diagnoses were not. Eyes with RD were more likely to experience hypotony (OR: 7.63; P < .0001), choroidal detachment (OR: 7.67; P < .0001), phthisis (OR: 7.69; P < .0001), and other serious complications. Surgical intervention was possible in 16 of the 27 RD cases, with pneumatic retinopexy being the most common approach. Retinal detachment is a significant complication following KPro implantation, particularly in patients with aniridia. Postoperative hypotony and other inflammatory complications may contribute to increased RD risk and challenge surgical repair. Close monitoring of high-risk patients may help mitigate long-term visual morbidity.
Purpose: Primary acquired melanosis (PAM) and pterygia are ocular surface lesions associated with sun exposure, with distinct clinical and histopathological features. This study aims to determine the incidence of PAM within pathology specimens of presumed benign pterygium cases at a tertiary center in Montreal. Methods: A retrospective cohort study of all consecutive patients undergoing pterygium excision at a tertiary care center between 2010 and 2023 was performed. Pathology reports of excised pterygium samples were reviewed, with data collected on age, sex, and histopathological findings. Ethics approval was obtained from the institutional review board, and no patients were excluded. Results: Among 1695 excised pterygia, 1277 (75.3%) specimens were submitted for pathology. Most were confirmed as pterygia (1230 samples, 96%). There were 40 unexpected findings (3.2%) including nevus or melanosis (13 cases), Salzmann nodules (5 cases), and ocular surface squamous neoplasia (4 cases). Two cases of PAM were identified: one with atypia in a 68-year-old French-Canadian man and another with no atypia in a 74-year-old Greek man. Conclusions: The low incidence of PAM observed highlights its rarity in presumed benign pterygium specimens. However, the identification of PAM with atypia emphasizes the need for routine pathological evaluation of all excised pterygia, even in the absence of clinical suspicion, due to the significant differences in management required for PAM.